Arcturus Therapeutics Holdings Inc. Stock price




Biotechnology & Medical Research

Market Closed - Nasdaq 04:00:00 2023-12-08 pm EST Intraday chart for Arcturus Therapeutics Holdings Inc. 5-day change 1st Jan Change
23.79 USD -0.96% -4.34% +40.27%
Sales 2023 * 174M Sales 2024 * 159M Capitalization 636M
Net income 2023 * -40M Net income 2024 * -85M EV / Sales 2023 *
Net cash position 2023 * - Net cash position 2024 * - EV / Sales 2024 *
P/E ratio 2023 *
P/E ratio 2024 *
Employees 170
Yield 2023 *
Yield 2024 *
Free-Float 91.09%
More Fundamentals * Assessed data
Dynamic Chart
Japan's Ministry of Health, Labour and Welfare Approves CSL and Arcturus Therapeutics' ARCT-154, the First Self-Amplifying mRNA Vaccine Approves for COVID in Adults CI
Sector Update: Health Care Stocks Softer Monday Afternoon MT
Arcturus Therapeutics Says FDA Grants Orphan Drug Designation for ARCT-032 to Treat Cystic Fibrosis MT
Arcturus Therapeutics Gets FDA Orphan Designation for ARCT-032 in Cystic Fibrosis DJ
Japan panel recommends approval of updated Daiichi Sankyo COVID shot- Kyodo RE
Sector Update: Health Care Stocks Mixed Pre-Bell Wednesday MT
Arcturus Therapeutics Q3 Net Loss Narrows as Revenue Surges; Shares Soar Premarket MT
Arcturus Therapeutics Q3 Net Loss Narrows as Revenue Surges MT
Transcript : Arcturus Therapeutics Holdings Inc., Q3 2023 Earnings Call, Nov 14, 2023 CI
Arcturus Therapeutics Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Earnings Flash (ARCT) ARCTURUS THERAPEUTICS HOLDINGS Posts Q3 Revenue $45.1M, vs. Street Est of $15.9M MT
Arcturus Therapeutics Holdings Insider Sold Shares Worth $128,062, According to a Recent SEC Filing MT
Arcturus Therapeutics Joint Venture mRNA Manufacturing Partner, ARCALIS, Wins Additional Financial Grants from Japanese Government CI
Arcturus Therapeutics and Cystic Fibrosis Foundation Extend Agreement to Advance ARCT-032, an Investigational Messenger RNA Therapeutic to Treat Cystic Fibrosis CI
Arcturus Therapeutics Holdings Inc. announced that it has received $25 million in funding from Cystic Fibrosis Foundation CI
More news
1 day-0.96%
1 week-4.34%
Current month-0.63%
1 month+22.63%
3 months-24.62%
6 months-16.20%
Current year+40.27%
More quotes
1 week
Extreme 22.7008
1 month
Extreme 17.52
Current year
Extreme 14.21
1 year
Extreme 14.21
3 years
Extreme 11.7
5 years
Extreme 4.11
10 years
Extreme 4.11
More quotes
Managers TitleAgeSince
Chief Executive Officer 51 2013
Director of Finance/CFO 58 2019
Chief Tech/Sci/R&D Officer - 2021
Members of the board TitleAgeSince
Director/Board Member 82 2019
Director/Board Member 64 2018
Chairman 80 2018
More insiders
Date Price Change Volume
23-12-08 23.79 -0.96% 329,477
23-12-07 24.02 +2.47% 241,560
23-12-06 23.44 +2.09% 1,410,750
23-12-05 22.96 -4.29% 259,824
23-12-04 23.99 -3.54% 264,903

Delayed Quote Nasdaq, December 08, 2023 at 04:00 pm EST

More quotes
Arcturus Therapeutics Holdings Inc. is a global late-stage clinical messenger RNA medicines and vaccine company. The Company is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its messenger RNA (mRNA) platform, its lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid medicines, and its self-amplifying mRNA technology (Self-Transcribing and Replicating RNA (STARR), technology) has the potential to provide longer-lasting RNA and sustained protein expression at lower dose level. It is leveraging its LUNAR platform and its nucleic acid technologies to develop and advance a pipeline of mRNA-based vaccines and therapeutics for infectious diseases and rare genetic disorders with significant unmet medical needs. Its COVID-19 vaccine candidate, which is based on its STARR technology platform is through Phase II clinical trials.
More about the company
Trading Rating :
Investor Rating :
ESG Refinitiv :
More Ratings
Mean consensus
Number of Analysts
Last Close Price
Average target price
Spread / Average Target
  1. Stock
  2. Equities
  3. Stock Arcturus Therapeutics Holdings Inc. - Nasdaq
Secure and Increase the Performance of your Investments with our Team of Experts at your Side
Securing my Investments